Physician profile
Aimee Diaz
NPI 1992224794
$1,544.89
in general payments reported to CMS, 2019-2025
14 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $166 · 2022: $202 · 2023: $380 · 2024: $349 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,175.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $428.37 | 2022-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $218.87 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $197.44 | 2023-2024 | Xarelto |
| Lilly USA, LLC | $130.28 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $117.81 | 2021-2025 | Farxiga, Breztri |
| Amarin Pharma, INC. | $114.97 | 2021-2023 | |
| Amgen INC. | $100.76 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Sumitomo Pharma America, INC. | $86.23 | 2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $38.21 | 2021-2022 | |
| Eisai INC. | $36.35 | 2025 | |
| Boston Scientific Corporation | $30.08 | 2025 | Bodyguardian |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.60 | 2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $13.89 | 2023 | Rexulti |
| Glaxosmithkline, LLC. | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.